RxDoctor Payments Data

Hari Bogabathina, MD

Cardiovascular Disease · Youngsville, LANPI 1083714836

Payments from drug & device makers

$4,992in general payments, 2019–2025

Across 92 payments — averaging $54.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Philips North America LLC$586
  • Abiomed$543
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$278
  • Novartis$171
  • Amgen$111
  • plus $678 from 12 others

What the payments were for

  • Travel & lodging$2,01640%
  • Food & beverage$2,97660%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,992 in reported general payments places this provider in the 55th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$116,595
Medicare patients
869
Services billed
1,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$58,958
EntrestoSacubitril/Valsartan64$44,959
BrilintaTicagrelor19$9,998
Nifedipine ErNifedipine104$1,676
Carvedilol128$566
Diltiazem 24hr Er (Cd)Diltiazem Hcl20$532
Isosorbide Mononitrate ErIsosorbide Mononitrate87$468
Atorvastatin Calcium60$372
ClopidogrelClopidogrel Bisulfate80$328
Metoprolol Succinate41$302
Potassium Chloride15$275
Lisinopril44$259
Losartan Potassium58$197
Metoprolol Tartrate62$149
Rosuvastatin Calcium13$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$58,95890 claims
NovartisEntresto$171$44,95964 claims
AstraZenecaBrilinta$24$9,99819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Youngsville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →